294 related articles for article (PubMed ID: 36127137)
21. CGRP and migraine: from bench to bedside.
Edvinsson L
Rev Neurol (Paris); 2021 Sep; 177(7):785-790. PubMed ID: 34275653
[TBL] [Abstract][Full Text] [Related]
22. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
Tringali G; Navarra P
Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
[TBL] [Abstract][Full Text] [Related]
23. [Anti-calcitonin generelated peptide (CGRP) therapies for migraine].
Moisset X; Demarquay G
Rev Prat; 2023 Feb; 73(2):123-126. PubMed ID: 36916250
[TBL] [Abstract][Full Text] [Related]
24. Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review.
Murray AM; Stern JI; Robertson CE; Chiang CC
Curr Pain Headache Rep; 2022 Oct; 26(10):783-794. PubMed ID: 36063264
[TBL] [Abstract][Full Text] [Related]
25. Medications Approved for Preventing Migraine Headaches.
Spindler BL; Ryan M
Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
[TBL] [Abstract][Full Text] [Related]
26. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
Charleston L; Talon B; Sullivan C; Anderson C; Kymes S; Regnier SA; Soni-Brahmbhatt S; Nahas SJ
J Headache Pain; 2023 Aug; 24(1):101. PubMed ID: 37532991
[TBL] [Abstract][Full Text] [Related]
27. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A
Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
[TBL] [Abstract][Full Text] [Related]
28. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
Maasumi K; Michael RL; Rapoport AM
Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
Jiang Y; Huang ZL
Medicine (Baltimore); 2022 Jun; 101(24):e29361. PubMed ID: 35713436
[TBL] [Abstract][Full Text] [Related]
30. Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines.
Henson B; Hollingsworth H; Nevois E; Herndon C
J Pain Palliat Care Pharmacother; 2020 Mar; 34(1):22-31. PubMed ID: 31763951
[TBL] [Abstract][Full Text] [Related]
31. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
Arca K; Reynolds J; Sands KA; Shiue HJ
Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
[No Abstract] [Full Text] [Related]
32. New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy.
Lee MJ; Al-Karagholi MA; Reuter U
Cephalalgia; 2023 Feb; 43(2):3331024221146315. PubMed ID: 36759320
[TBL] [Abstract][Full Text] [Related]
33. The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review.
Vig SJ; Garza J; Tao Y
Headache; 2022 Nov; 62(10):1256-1263. PubMed ID: 35467013
[TBL] [Abstract][Full Text] [Related]
34. Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.
Bedrin K; Ailani J; Dougherty C
Headache; 2022 Nov; 62(10):1419-1423. PubMed ID: 36426766
[TBL] [Abstract][Full Text] [Related]
35. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Yuan H; Spare NM; Silberstein SD
Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
[TBL] [Abstract][Full Text] [Related]
36. Preventive Treatment of Migraine.
Lipton RB
Continuum (Minneap Minn); 2024 Apr; 30(2):364-378. PubMed ID: 38568488
[TBL] [Abstract][Full Text] [Related]
37. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
[TBL] [Abstract][Full Text] [Related]
38. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
40. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC
Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
